These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36712843)

  • 1. Autologous stem cell transplantation (ASCT) outcome for multiple myeloma in a tertiary referral centre in Malaysia.
    Liam CCK; Boo YL; Lee YL; Law KB; Ho KW; Shahnaz SAKS; Tan JTC; Lau NS; Ong TC; Tan SM; Sathar J
    Blood Cell Ther; 2021 Feb; 4(1):1-8. PubMed ID: 36712843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis.
    Suzuki K; Shimazu Y; Minakata D; Ikeda T; Takahashi H; Tsukada N; Kanda Y; Doki N; Nishiwaki K; Miwa A; Sawa M; Kataoka K; Hiramoto N; Ota S; Itagaki M; Ichinohe T; Atsuta Y; Yano S; Kawamura K;
    Transplant Cell Ther; 2023 Nov; 29(11):688.e1-688.e13. PubMed ID: 37574125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
    Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
    Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
    Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
    Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
    Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
    Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.
    Hsu TL; Tsai CK; Liu CY; Yeh CM; Lin FL; Hsiao LT; Liu YC; Chien SH; Wang HY; Ko PS; Lin TA; Chen WC; Chen PM; Liu JH; Gau JP; Liu CJ
    Ann Hematol; 2024 Aug; 103(8):2893-2904. PubMed ID: 38472362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
    Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
    Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 15. Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients.
    Abdrabou AK; Al Sharif F; El Fakih R; Zahrani HA; Al Yamany R; Saleh M; Alhayli S; Al Somali Z; Alotaibi A; AlShaibani A; Deeba F; Asif M; Ahmed SAOA; Al Fraih F; Shaheen M; Alahmari A; Rasheed W; Chaudhri NA; Al Mohareb F; Aljurf M; Hanbali A
    Ann Saudi Med; 2024; 44(2):93-103. PubMed ID: 38615184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma.
    Liu J; Li J; Huang B; Zheng D; Chen M; Zhou Z; Xu D; Zou W
    Chin J Cancer Res; 2013 Apr; 25(2):166-74. PubMed ID: 23592897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
    Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
    JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of autologous transplant with non-cryopreserved peripheral blood stem cells in myeloma and lymphoma in Algeria. 10 years' experience.
    Bekadja MA; Entasoltan B; Amani K; Ouldjeriouat H; Osmani S; Bouchama S; Charef L; Arabi A; Brahimi M; Bouhass AR; Yafour N
    Tunis Med; 2022 Novembre; 100(11):762-768. PubMed ID: 37551517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
    Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.